Efficacy of combined histone deacetylase and checkpoint kinase inhibition in a preclinical model of human Burkitt lymphoma

Yan Guo Kong, Gustavo Barisone, Ranjit S. Sidhu, Robert T O'Donnell, Joseph Tuscano

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Checkpoint kinase inhibition has been studied as a way of enhancing the effectiveness of DNA-damaging agents. More recently, histone deacetylase inhibitors have shown efficacy in several cancers, including non-Hodgkin lymphoma. To evaluate the effectiveness of this combination for the treatment of lymphoma, we examined the combination of AR42, a histone deacetylase inhibitor, and checkpoint kinase 2 (CHEK2) inhibitor II in vitro and in vivo. The combination resulted in up to 10-fold increase in potency in five Burkitt lymphoma cell lines when compared with either drug alone. Both drugs inhibited tumor progression in xenograft models, but the combination was more effective than either agent alone, resulting in regression of established tumors. No toxicity was observed. These results suggest that the combination of histone deacetylase inhibition and checkpoint kinase inhibition represent an effective and nontoxic treatment option that should be further explored in preclinical and clinical studies.

Original languageEnglish (US)
Pages (from-to)824-832
Number of pages9
JournalMolecular Medicine
Volume21
DOIs
StatePublished - Aug 24 2015

Fingerprint

Histone Deacetylases
Burkitt Lymphoma
Histone Deacetylase Inhibitors
Phosphotransferases
Checkpoint Kinase 2
Neoplasms
Heterografts
Pharmaceutical Preparations
Non-Hodgkin's Lymphoma
Lymphoma
Cell Line
DNA

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Efficacy of combined histone deacetylase and checkpoint kinase inhibition in a preclinical model of human Burkitt lymphoma. / Kong, Yan Guo; Barisone, Gustavo; Sidhu, Ranjit S.; O'Donnell, Robert T; Tuscano, Joseph.

In: Molecular Medicine, Vol. 21, 24.08.2015, p. 824-832.

Research output: Contribution to journalArticle

@article{bad98f94979c412b83ae894c4ae2d519,
title = "Efficacy of combined histone deacetylase and checkpoint kinase inhibition in a preclinical model of human Burkitt lymphoma",
abstract = "Checkpoint kinase inhibition has been studied as a way of enhancing the effectiveness of DNA-damaging agents. More recently, histone deacetylase inhibitors have shown efficacy in several cancers, including non-Hodgkin lymphoma. To evaluate the effectiveness of this combination for the treatment of lymphoma, we examined the combination of AR42, a histone deacetylase inhibitor, and checkpoint kinase 2 (CHEK2) inhibitor II in vitro and in vivo. The combination resulted in up to 10-fold increase in potency in five Burkitt lymphoma cell lines when compared with either drug alone. Both drugs inhibited tumor progression in xenograft models, but the combination was more effective than either agent alone, resulting in regression of established tumors. No toxicity was observed. These results suggest that the combination of histone deacetylase inhibition and checkpoint kinase inhibition represent an effective and nontoxic treatment option that should be further explored in preclinical and clinical studies.",
author = "Kong, {Yan Guo} and Gustavo Barisone and Sidhu, {Ranjit S.} and O'Donnell, {Robert T} and Joseph Tuscano",
year = "2015",
month = "8",
day = "24",
doi = "10.2119/molmed.2015.00032",
language = "English (US)",
volume = "21",
pages = "824--832",
journal = "Molecular Medicine",
issn = "1076-1551",
publisher = "Feinstein Institute for Medical Research",

}

TY - JOUR

T1 - Efficacy of combined histone deacetylase and checkpoint kinase inhibition in a preclinical model of human Burkitt lymphoma

AU - Kong, Yan Guo

AU - Barisone, Gustavo

AU - Sidhu, Ranjit S.

AU - O'Donnell, Robert T

AU - Tuscano, Joseph

PY - 2015/8/24

Y1 - 2015/8/24

N2 - Checkpoint kinase inhibition has been studied as a way of enhancing the effectiveness of DNA-damaging agents. More recently, histone deacetylase inhibitors have shown efficacy in several cancers, including non-Hodgkin lymphoma. To evaluate the effectiveness of this combination for the treatment of lymphoma, we examined the combination of AR42, a histone deacetylase inhibitor, and checkpoint kinase 2 (CHEK2) inhibitor II in vitro and in vivo. The combination resulted in up to 10-fold increase in potency in five Burkitt lymphoma cell lines when compared with either drug alone. Both drugs inhibited tumor progression in xenograft models, but the combination was more effective than either agent alone, resulting in regression of established tumors. No toxicity was observed. These results suggest that the combination of histone deacetylase inhibition and checkpoint kinase inhibition represent an effective and nontoxic treatment option that should be further explored in preclinical and clinical studies.

AB - Checkpoint kinase inhibition has been studied as a way of enhancing the effectiveness of DNA-damaging agents. More recently, histone deacetylase inhibitors have shown efficacy in several cancers, including non-Hodgkin lymphoma. To evaluate the effectiveness of this combination for the treatment of lymphoma, we examined the combination of AR42, a histone deacetylase inhibitor, and checkpoint kinase 2 (CHEK2) inhibitor II in vitro and in vivo. The combination resulted in up to 10-fold increase in potency in five Burkitt lymphoma cell lines when compared with either drug alone. Both drugs inhibited tumor progression in xenograft models, but the combination was more effective than either agent alone, resulting in regression of established tumors. No toxicity was observed. These results suggest that the combination of histone deacetylase inhibition and checkpoint kinase inhibition represent an effective and nontoxic treatment option that should be further explored in preclinical and clinical studies.

UR - http://www.scopus.com/inward/record.url?scp=84975112997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975112997&partnerID=8YFLogxK

U2 - 10.2119/molmed.2015.00032

DO - 10.2119/molmed.2015.00032

M3 - Article

AN - SCOPUS:84975112997

VL - 21

SP - 824

EP - 832

JO - Molecular Medicine

JF - Molecular Medicine

SN - 1076-1551

ER -